The expression of ras oncogene in normal and pathological liver disease

Activation of the ras oncogene is associated with overproduction of the normal gene product (p21). Ninety one paraffin-embedded specimens were used to map the distribution of the normal form of p21 in normal, inflamed, cirrhotic and carcinomatous liver parenchyma. Monoclonal antibodies (Mo-RAP) were raised against the normal form of the ras-oncogene product and histological sections were stained by the peroxidase-antiperoxidase technique. Normal, inflamed and cirrhotic liver showed either minimal or moderate cytoplasmic staining. By contrast primary (n = 13) and secondary (n = 41) liver carcinomas exhibited intense staining. The differential pattern observed in p21 distribution could have useful clinical applications.     

Mastopathia cystica chronica im Hinblick auf krebsige Entartung

Zusammenfassung Als Beitrag zur Frage eines Überganges der Cystenmamma in Carcinom werden in der vorliegenden Arbeit 381 Fälle mit klinisch einwandfrei cystischen Veränderungen der Brustdrüse aus der Chirurgischen Universitätsklinik Jena der Jahre 1920–1946 zusammengestellt unddie histologisch bewiesenen Fälle (169) zu Besprechungen herangezogen. Dabei zeigte sich, daßin 7,1% der Fälle die Mastopathia cystica einenKrebs oder krebsartige Veränderungen aufweist. Nach diesem Häufigkeitsverhältnis können wir diese Erkrankung nicht als Präcarcinomatose oder als Erkrankung, auf deren Boden sich ein Krebs prädisponiert entwickelt, ansprechen. Die Tatsache aber allein der Krebsentwicklung mahnt zur Vorsicht und weist die damit sich ergebende Behandlung, die kurz aufgezeichnet wird. Nachuntersuchungen und Anfragen bestätigen das gefundene Ergebnis.     

Studie über die Aetiologie und Pathogenese der sogenannten generalisirten Vaccine bei Individuen mit vorher gesunder oder kranker Haut

Ohne ZusammenfassungHiezu Taf. I–V.     

Ueber die verschliessung des Schlundes beim Sprechen

Ohne ZusammenfassungHierzu Taf. I–III.Anmerkung des Herausgebers. Diese Abhandlung ist vor dem Erscheinen der neuesten Schrift des Herrn v. Luschka über den Schlundkopf eingesendet worden.     

Ueber die vasomotorischen Wirkungen des Nervus vagus,laryngeus und sympathicus

Ohne Zusammenfassung     

Spontane Heilung einer Hydrocele unter dem Einfluss von Variola

Ohne Zusammenfassung     

Apheresis Technologies: An International Perspective

Abstract: The developments in apheresis techniques and their clinical applications world-wide are technologically driven. In the past, apheresis survey statistics have highlighted both the differences by region in clinical practice and in the types of technologies utilized. Such differences have provided a basis for the scientific and clinical assessments of these apheresis technologies and their clinical outcomes and have stimulated the marketing and business development of new technologies world-wide. A review of the regional practices and technologies utilized provides a perspective on the future role of apheresis and its developments in clinical practice. While technology is a driving force for the development of new techniques for clinical practice, it is not the only market force. For technology introduction, several other important issues need to be considered. Regulations at the local and, most importantly, the federal level impact the timing for new technology introduction. Reimbursement by healthcare payers is critically important from the initiation of the development of a technology through its clinical use. Clinical trials are critically important to show the safety and clinical- and cost-effectiveness of the technology in order for payers to provide reimbursement for its use, but these trials are sometimes long and costly. Research funding availability at the governmental and commercial levels critically impacts new technology investigation and its introduction. Apheresis technology developments offer new hopes and promises for the clinical team; however, their development, introduction, and utilization will be influenced by the prevailing market forces.     

Case series: Combined spinal epidural anesthesia for Cesarean delivery andex utero intrapartum treatment procedure

PURPOSE: To report the use of regional anesthesia and iv nitroglycerin to provide anesthesia and uterine relaxation for three Cesarean deliveries (CD) involving ex utero intrapartum treatment (EXIT) of potentially life-threatening airway obstruction in the newborn. CLINICAL FEATURES: Case 1--a 36-yr-old woman at 38 weeks' gestation was scheduled for an elective CD for fetal skeletal dysplasia and micrognathia. Case 2--a 34-yr-old woman at 35 weeks gestation had a fetal ultrasound revealing fixed neck flexion and micrognathia consistent with fetal arthrogryposis. Case 3--a 27-yr-old woman presented at 38 weeks gestation for CD for severe fetal micrognathia, with mandibular growth below the fifth percentile. For each case, a combined spinal epidural anesthetic was performed with 0.75% bupivacaine, fentanyl and morphine intrathecally followed by placement of a multiorifice epidural catheter. Prior to uterine incision patients received a loading dose followed by an iv infusion of nitroglycerin. Uterine relaxation was sufficient in all cases for delivery of the fetus, and allowed for evaluation by direct laryngoscopy and intubation while maintaining fetal-placental circulation. The surgical procedures were completed without incident. CONCLUSIONS: Anesthesia and uterine relaxation for CD and EXIT procedures can be safely provided with regional anesthesia and iv nitroglycerin.